| 06/07/26 | 16:45:00 | 6 Jul 2026 | | Directorate change |
| 22/06/26 | 07:00:10 | 22 Jun 2026 | | Preliminary Results |
| 16/06/26 | 07:00:08 | 16 Jun 2026 | | Notice of Results |
| 29/05/26 | 07:00:03 | 29 May 2026 | | MSA with Global Pharmaceutical Company |
| 18/05/26 | 07:00:07 | 18 May 2026 | | Collaboration with AdventHealth for two studies |
| 11/05/26 | 07:00:10 | 11 May 2026 | | Q1 trading update and outlook for 2026 |
| 30/04/26 | 07:00:10 | 30 Apr 2026 | | Confirmation of Q1 trading update |
| 20/04/26 | 07:00:07 | 20 Apr 2026 | | Research Collaboration with The Royal Marsden |
| 16/04/26 | 17:39:48 | 16 Apr 2026 | | Board changes - Replacement |
| 13/02/26 | 07:00:06 | 13 Feb 2026 | | Aligning Regulatory Approach with Commercial Needs |
| 16/01/26 | 07:00:06 | 16 Jan 2026 | | Preliminary Fourth Quarter 2025 Financial Results |
| 12/01/26 | 07:00:07 | 12 Jan 2026 | | Board changes |
| 23/12/25 | 09:15:05 | 23 Dec 2025 | | Holding(s) in Company |
| 19/12/25 | 17:51:11 | 19 Dec 2025 | | PDMR Dealing and ESOT Share Purchase |
| 15/12/25 | 14:41:11 | 15 Dec 2025 | | Results of General Meeting and Board Changes |
| 02/12/25 | 11:11:53 | 2 Dec 2025 | | Additional Subscription |
| 01/12/25 | 17:44:06 | 1 Dec 2025 | | Result of Retail Offer |
| 25/11/25 | 17:40:08 | 25 Nov 2025 | | Update to Admission of Fundraising Shares |
| 25/11/25 | 08:00:01 | 25 Nov 2025 | | Launch of Retail Offer |
| 25/11/25 | 07:55:39 | 25 Nov 2025 | | Result of Oversubscribed Placing and Subscription |
| 24/11/25 | 18:32:00 | 24 Nov 2025 | | Proposed Placing and Subscription |
| 18/11/25 | 07:00:09 | 18 Nov 2025 | | QIAGEN Collaboration and Co-Marketing Agreement |
| 05/11/25 | 18:16:02 | 5 Nov 2025 | | Further Update on Funding |
| 05/11/25 | 07:00:12 | 5 Nov 2025 | | CelLBxHealth Presents Proof-of-Concept Study |
| 04/11/25 | 07:00:11 | 4 Nov 2025 | | Expert Consensus on CTCs; Update on Funding |
| 29/10/25 | 07:00:11 | 29 Oct 2025 | | CHANGE OF NAME |
| 16/10/25 | 07:00:09 | 16 Oct 2025 | | Appointments: Interim CEO and senior board advisor |
| 08/10/25 | 07:00:10 | 8 Oct 2025 | | Strategy Update |
| 29/09/25 | 07:00:18 | 29 Sept 2025 | | Presentation of Data on Glioblastoma |
| 12/09/25 | 07:00:18 | 12 Sept 2025 | | Board Changes |
| 09/09/25 | 07:01:00 | 9 Sept 2025 | | Interim Results |
| 09/09/25 | 07:00:17 | 9 Sept 2025 | | Change of Adviser |
| 05/09/25 | 14:58:52 | 5 Sept 2025 | | Notice of Results |
| 20/08/25 | 07:00:03 | 20 Aug 2025 | | ANGLE announces collaboration with Myriad Genetics |
| 08/07/25 | 07:00:12 | 8 Jul 2025 | | PARSORTIX ENABLES STUDY OF CANCER PROGRESSION |
| 30/06/25 | 17:50:10 | 30 Jun 2025 | | Result of 2025 Annual General Meeting |
| 17/06/25 | 07:00:12 | 17 Jun 2025 | | EACR 2025: Innovation in AR expression profiling |
| 17/06/25 | 07:00:10 | 17 Jun 2025 | | EACR 2025: Data demonstrating DNA dual analysis |
| 10/06/25 | 07:00:14 | 10 Jun 2025 | | Novel discoveries into the biology of cancer |
| 09/06/25 | 07:00:10 | 9 Jun 2025 | | POSTING OF ANNUAL REPORT AND NOTICE OF AGM |
| 06/06/25 | 07:00:12 | 6 Jun 2025 | | Board Changes |
| 28/05/25 | 07:00:05 | 28 May 2025 | | Preliminary Results |
| 23/05/25 | 07:00:09 | 23 May 2025 | | Notice of Results |
| 28/04/25 | 07:00:09 | 28 Apr 2025 | | RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME |
| 21/03/25 | 07:00:10 | 21 Mar 2025 | | Issue of LTIP Options and Share Options |
| 21/03/25 | 07:00:08 | 21 Mar 2025 | | Results of Eisai Phase 2 pilot study |
| 06/02/25 | 07:00:07 | 6 Feb 2025 | | Novel findings using Parsortix |
| 29/01/25 | 07:00:04 | 29 Jan 2025 | | Analysis of CTC-DNA and ctDNA using Illumina assay |
| 24/01/25 | 10:05:00 | 24 Jan 2025 | | Parsortix used in research paper from ETH Zurich |
| 23/01/25 | 07:00:06 | 23 Jan 2025 | | Trading Update |
